Your browser doesn't support javascript.
loading
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.
Lam, Raymond W; Kennedy, Sidney H; Adams, Camelia; Bahji, Anees; Beaulieu, Serge; Bhat, Venkat; Blier, Pierre; Blumberger, Daniel M; Brietzke, Elisa; Chakrabarty, Trisha; Do, André; Frey, Benicio N; Giacobbe, Peter; Gratzer, David; Grigoriadis, Sophie; Habert, Jeffrey; Ishrat Husain, M; Ismail, Zahinoor; McGirr, Alexander; McIntyre, Roger S; Michalak, Erin E; Müller, Daniel J; Parikh, Sagar V; Quilty, Lena S; Ravindran, Arun V; Ravindran, Nisha; Renaud, Johanne; Rosenblat, Joshua D; Samaan, Zainab; Saraf, Gayatri; Schade, Kathryn; Schaffer, Ayal; Sinyor, Mark; Soares, Claudio N; Swainson, Jennifer; Taylor, Valerie H; Tourjman, Smadar V; Uher, Rudolf; van Ameringen, Michael; Vazquez, Gustavo; Vigod, Simone; Voineskos, Daphne; Yatham, Lakshmi N; Milev, Roumen V.
Afiliação
  • Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Kennedy SH; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Adams C; Department of Psychiatry, University of Saskatchewan, Saskatoon, SK, Canada.
  • Bahji A; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
  • Beaulieu S; Department of Psychiatry, McGill University, Montréal, QC, Canada.
  • Bhat V; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Blier P; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
  • Blumberger DM; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Brietzke E; Department of Psychiatry, Queen's University, Kingston, ON, Canada.
  • Chakrabarty T; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Do A; Department of Psychiatry, Université de Montréal, Montréal, QC, Canada.
  • Frey BN; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Giacobbe P; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Gratzer D; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Grigoriadis S; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Habert J; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
  • Ishrat Husain M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Ismail Z; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
  • McGirr A; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
  • McIntyre RS; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Michalak EE; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Müller DJ; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Parikh SV; Department of Psychiatry, University of Michigan, Ann Arbour, MI, USA.
  • Quilty LS; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Ravindran AV; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Ravindran N; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Renaud J; Department of Psychiatry, McGill University, Montréal, QC, Canada.
  • Rosenblat JD; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Samaan Z; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Saraf G; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
  • Schade K; Office of Research Services, Huron University, London, ON, Canada.
  • Schaffer A; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Sinyor M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Soares CN; Department of Psychiatry, Queen's University, Kingston, ON, Canada.
  • Swainson J; Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
  • Taylor VH; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
  • Tourjman SV; Department of Psychiatry, Université de Montréal, Montréal, QC, Canada.
  • Uher R; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • van Ameringen M; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Vazquez G; Department of Psychiatry, Queen's University, Kingston, ON, Canada.
  • Vigod S; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Voineskos D; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Yatham LN; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Milev RV; Department of Psychiatry, Queen's University, Kingston, ON, Canada.
Can J Psychiatry ; 69(9): 641-687, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38711351
ABSTRACT

BACKGROUND:

The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate new evidence and provide new and revised recommendations for the assessment and management of MDD in adults.

METHODS:

CANMAT convened a guidelines editorial group comprised of academic clinicians and patient partners. A systematic literature review was conducted, focusing on systematic reviews and meta-analyses published since the 2016 guidelines. Recommendations were organized by lines of treatment, which were informed by CANMAT-defined levels of evidence and supplemented by clinical support (consisting of expert consensus on safety, tolerability, and feasibility). Drafts were revised based on review by patient partners, expert peer review, and a defined expert consensus process.

RESULTS:

The updated guidelines comprise eight primary topics, in a question-and-answer format, that map a patient care journey from assessment to selection of evidence-based treatments, prevention of recurrence, and strategies for inadequate response. The guidelines adopt a personalized care approach that emphasizes shared decision-making that reflects the values, preferences, and treatment history of the patient with MDD. Tables provide new and updated recommendations for psychological, pharmacological, lifestyle, complementary and alternative medicine, digital health, and neuromodulation treatments. Caveats and limitations of the evidence are highlighted.

CONCLUSIONS:

The CANMAT 2023 updated guidelines provide evidence-informed recommendations for the management of MDD, in a clinician-friendly format. These updated guidelines emphasize a collaborative, personalized, and systematic management approach that will help optimize outcomes for adults with MDD.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article